Skip to content
Junction Bioscience logo

Junction Bioscience

Junction Bioscience is a YC Winter 2024 (W24) company. Team of 1.

About Junction Bioscience

GPAgent's own fund-neutral profile, written from public information. Updated Oct 5, 2026.

Summary

Junction Bioscience builds an autonomous AI system that generates and iterates on scientific hypotheses to guide small-molecule drug discovery. It targets the neuroinflammation and immunology space, where the platform works to map the molecular drivers of disease and identify therapeutic candidates. The work it replaces is the slow, largely manual cycle of hypothesis generation and experimental design that characterizes early-stage medicinal chemistry research.

From the Y Combinator listing

How Junction Bioscience describes itself in Y Combinator's public directory. Original listing (opens in a new tab)

AI Hypothesis Engine for Molecular Discovery

Junction Bioscience is building an autonomous AI scientist to navigate the discovery of transformative medicines. Our scientific hypothesis engine iterates upon breakthrough chemistry from the laboratory to achieve clarity and control over the molecular basis of disease. We focus on the intersection of neuroinflammation and immunology where uncommon molecular insights position us to develop best-in-class therapies for millions of patients in need.

Facts

Industry
Healthcare / Healthcare -> Therapeutics
Team size
1
Status
Active
Stage
Early

Founders (1)

Score every batch against your own thesis

GPAgent's sourcing agent reads every company in a batch, scores each one against your fund's thesis in a private workspace, and lines up the founders worth meeting before Demo Day. You decide who to contact. Your scores, notes, and pipeline never appear on these pages.

How Accelerator intelligence works